Moreover, Garcia-Fontana et al. showed that patients undergoing androgen deprivation therapy (ADT) had significantly higher sclerostin levels compared to prostate cancer patients without ADT treatment: ADT 64.52 ± 27.21 pmol/l, non-ADT 48.24 ± 15.93 pmol/l, healthy controls 38.48 ± 9.19 pmol/l, p < 0.05. This evidence concerns the gene SOST and prostate carcinoma.